Poor Candidates for GLP-1 Receptor Agonist Initiation
Patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN2) should not receive GLP-1 receptor agonists, as these are absolute contraindications for most agents in this class. 1, 2
Absolute Contraindications
The following patients should not be initiated on GLP-1 RAs:
- Personal or family history of medullary thyroid cancer (all long-acting agents: semaglutide, liraglutide, exenatide ER, dulaglutide) 1, 2, 3
- Multiple endocrine neoplasia syndrome type 2 (MEN2) (same agents as above) 1, 2
- History of serious hypersensitivity reaction to the specific GLP-1 RA 1
- Severe renal impairment or ESRD for exenatide and lixisenatide specifically 1
Strong Relative Contraindications (Consider Alternative Agents)
These patients are poor candidates and alternative therapies should be strongly preferred:
Gastrointestinal Conditions
- History of gastroparesis - GLP-1 RAs delay gastric emptying, which will worsen symptoms 1, 4
- Persistent nausea despite low doses and dietary education - 5-10% of patients discontinue due to GI side effects 2
- Active gallbladder disease 4
- Prior gastric surgery - altered anatomy increases risk of complications 1
Pancreatic History
- History of pancreatitis - while causality is not established, prescribing information recommends considering other agents 2, 3
- History of pancreatic cancer - theoretical risk from preclinical models 5
Retinal Disease
- History of proliferative diabetic retinopathy when considering semaglutide or dulaglutide specifically - associated with retinopathy complications related to rapid A1C reduction 1, 4
Pregnancy and Lactation
Important Clinical Cautions
While not absolute contraindications, exercise heightened caution in:
Renal Impairment
- Severe renal impairment or ESRD for liraglutide and semaglutide - use with caution, though not contraindicated 1
- Limited data exist for severe CKD, though newer evidence suggests GLP-1 RAs can be used down to eGFR 15 ml/min/1.73 m² 6, 5
Hypoglycemia Risk
- Patients on insulin or sulfonylureas - reduce insulin dose by ~20% or sulfonylurea by 50% when initiating to prevent hypoglycemia 1, 4, 1
- Well-controlled A1C at baseline - same dose reduction strategy applies 1, 4
Malnutrition Risk
- Patients at risk for malnutrition - GLP-1 RAs cause weight loss and can worsen nutritional status in advanced CKD or frail patients 5
Common Pitfalls to Avoid
Do not combine with DPP-4 inhibitors - discontinue DPP-4 inhibitor before starting GLP-1 RA 1, 6
Start low and titrate slowly - this mitigates GI side effects, which are the most common reason for discontinuation 1, 4, 3
Do not assume all GLP-1 RAs have the same contraindications - shorter-acting agents (exenatide twice daily, lixisenatide) are NOT contraindicated in MEN2 or medullary thyroid cancer 2
Avoid in patients who cannot tolerate injection-related therapies - all current GLP-1 RAs except oral semaglutide require subcutaneous injection 2
Consider cost and access - these medications are expensive and may not be accessible in resource-limited settings, making them poor choices when alternatives exist 7
When to Strongly Prefer Alternative Agents
Choose SGLT2 inhibitors or other glucose-lowering agents instead when:
- Patient has significant CKD with eGFR <45 ml/min/1.73 m² and glycemic efficacy is the primary goal (though GLP-1 RAs can still be used for CV/renal benefits) 1
- History of recurrent severe nausea or vomiting with previous GI medications
- Patient refuses injectable therapy and oral semaglutide is not available or appropriate
- Any absolute contraindication listed above exists
The decision framework should prioritize patient safety first, then cardiovascular and renal benefits (which favor GLP-1 RAs in most patients with established ASCVD), and finally glycemic efficacy and tolerability.